全球女性健康治疗市场规模、份额、成长分析、按治疗领域、按适应症、按配销通路- 行业预测 2024-2031

2022年，全球女性健康治疗市场规模为129.8亿美元，预计将从2023年的137亿美元成长到2031年的210.5亿美元，预测期间（2024-2031年）复合CAGR为5.52%。

全球女性健康治疗市场涵盖多种药物和治疗方法，旨在解决女性在生命不同阶段所面临的独特健康需求和挑战。随着人们对女性健康问题的日益关注，近年来，在意识提高、医疗技术进步和医疗保健政策不断变化等因素的推动下，这个市场领域出现了显着扩张。从生殖健康和避孕到更年期管理和骨质疏鬆症治疗，市场提供了广泛的治疗选择，以满足女性的特定需求。近年来，人们更加重视针对主要影响女性的疾病的研发工作，例如乳癌和子宫颈癌、卵巢疾病以及狼疮和类风湿性关节炎等自体免疫疾病等。此外，人们越来越认识到整体方法对妇女健康的重要性，其中不仅包括医疗干预措施，还包括生活方式的改变、心理健康支持以及获得教育和预防性护理。儘管取得了重大进展，但女性健康治疗市场仍然存在挑战，包括获得医疗保健服务的差异、临床试验中女性代表性不足以及围绕某些健康问题的耻辱。应对这些挑战需要医疗保健提供者、政策制定者、製药公司和倡导团体的共同努力，以确保全世界妇女能够公平地获得优质护理并全面支持其健康需求。展望未来，全球女性健康治疗市场的未来似乎充满希望，医学研究、技术和医疗保健服务的持续进步预计将推动创新并改善全球女性的治疗结果。然而，要取得有意义的进展，就需要在研究、教育和宣传工作方面持续合作和投资，以使妇女能够掌控自己的健康和福祉。透过将妇女健康作为公共卫生议程和医疗保健系统的核心组成部分，我们可以努力实现一个所有妇女都能获得照护和支持的未来，她们需要过着健康、充实的生活。

目录

执行摘要

• 市场概况
• 命运之轮

研究方法论

• 资讯采购
• 二手和主要资料来源
• 市场规模估计
• 市场假设与限制

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战

主要市场洞察

• 技术分析
• 定价分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• 启动分析
• 原料分析
• 创新矩阵
• 管道产品分析
• 总体经济指标
• 顶级投资分析
• 成功的关键因素
• 竞争程度

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战
• 监管环境
• 波特分析
• 对未来颠覆的特别见解

按治疗领域分類的全球女性健康治疗市场

• 市场概况
• 荷尔蒙疗法
• 避孕药具
• 生殖健康药物
• 其他的

按适应症分類的全球女性健康治疗市场

• 市场概况
• 停经
• 避孕
• 荷尔蒙相关癌症
• 生殖障碍
• 和别的

按配销通路分類的全球女性健康治疗市场

• 市场概况
• 医院药房
• 零售药局
• 网路药局
• 和别的

全球女性健康治疗市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • MEA 的其余部分

竞争格局

• 前 5 名玩家比较
• 2021 年关键参与者的市场定位
• 主要市场参与者所采取的策略
• 最佳制胜策略
• 近期市集活动
• 主要公司市占率（%），2021年

主要公司简介

• Pfizer Inc. (United States)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• GlaxoSmithKline plc (United Kingdom)
• Merck & Co., Inc. (United States)
• AbbVie Inc. (United States)
• Eli Lilly and Company (United States)
• AstraZeneca plc (United Kingdom)
• Johnson & Johnson (United States)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Eisai Co., Ltd. (Japan)
• Otsuka Pharmaceutical Co., Ltd. (Japan)
• Shionogi & Co., Ltd. (Japan)
• Mitsubishi Tanabe Pharma Corporation (Japan)
• Daiichi Sankyo Company, Limited (Japan)
• Astellas Pharma Inc. (Japan)
• Sanofi (France)
• Bristol Myers Squibb Company (United States)
• Allergan plc (Ireland)

Global Women's Health Therapeutics Market size was valued at USD 12.98 billion in 2022 and is poised to grow from USD 13.70 billion in 2023 to USD 21.05 billion by 2031, growing at a CAGR of 5.52% in the forecast period (2024-2031).

The global women's health therapeutics market encompasses a diverse array of pharmaceuticals and treatments aimed at addressing the unique health needs and challenges faced by women across different stages of life. With an ever-growing focus on women's health issues, this market segment has seen significant expansion in recent years, driven by factors such as increasing awareness, advancements in medical technology, and evolving healthcare policies. From reproductive health and contraception to menopause management and osteoporosis treatment, the market offers a wide range of therapeutic options tailored to meet the specific needs of women. In recent times, there has been a heightened emphasis on research and development efforts targeting conditions that predominantly affect women, such as breast and cervical cancers, ovarian disorders, and autoimmune diseases like lupus and rheumatoid arthritis, among others. Additionally, there is a growing recognition of the importance of holistic approaches to women's health, which encompass not only medical interventions but also lifestyle modifications, mental health support, and access to education and preventive care. Despite significant progress, challenges persist in the women's health therapeutics market, including disparities in access to healthcare services, underrepresentation of women in clinical trials, and stigma surrounding certain health issues. Addressing these challenges requires a concerted effort from healthcare providers, policymakers, pharmaceutical companies, and advocacy groups to ensure equitable access to quality care and comprehensive support for women's health needs worldwide. Looking ahead, the future of the global women's health therapeutics market appears promising, with continued advancements in medical research, technology, and healthcare delivery expected to drive innovation and improve outcomes for women across the globe. However, achieving meaningful progress will require ongoing collaboration and investment in research, education, and advocacy efforts to empower women to take charge of their health and well-being. By prioritizing women's health as a central component of public health agendas and healthcare systems, we can work towards a future where all women have access to the care and support, they need to live healthy, fulfilling lives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Women's Health Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Women's Health Therapeutics Market Segmental Analysis

The global women's health therapeutics market is segmented into four major segments i.e. by therapeutic area, indication, distribution channel, and region. Based on type, it is divided into hormone therapies, contraceptives, reproductive health drugs, and others. Based on Indication, it is bifurcated as menopause, contraception, hormone-related cancers, reproductive disorders, and others. Based on distribution channel it is segregated into, hospital pharmacies, retail pharmacies, online pharmacies, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Drivers of the Global Women's Health Therapeutics Market

One significant driver propelling the growth of the global women's health therapeutics market is increasing awareness and advocacy for women's health issues. Over the past decade, there has been a notable surge in public awareness campaigns, educational initiatives, and policy efforts aimed at addressing women's health concerns. This heightened awareness has led to improved diagnosis rates, greater access to healthcare services, and increased demand for innovative therapies tailored to women's specific needs. Additionally, advancements in medical research and technology have expanded the scope of treatment options available, driving market growth further.

Restraints in the Global Women's Health Therapeutics Market

However, alongside these drivers, several restraints challenge the market's expansion. One notable restraint is the lingering stigma and cultural barriers surrounding women's health issues in many parts of the world. Societal taboos, misconceptions, and cultural norms can hinder women from seeking timely medical care or discussing their health concerns openly. Addressing these barriers requires comprehensive education and awareness campaigns, as well as culturally sensitive approaches to healthcare delivery.

Market Trends of the Global Women's Health Therapeutics Market

Moreover, a significant trend shaping the women's health therapeutics market is the growing emphasis on personalized medicine and precision healthcare. As our understanding of genetic predispositions and individual variations in drug responses improves, there is a shift towards tailored treatment approaches that consider each patient's unique biology, lifestyle, and health history. This trend is driving investments in genomic medicine, biomarker research, and targeted therapies, enabling more precise and effective interventions for women's health conditions. Additionally, the integration of digital health technologies, such as mobile apps and wearable devices, is enhancing patient engagement, remote monitoring, and data-driven healthcare decision-making, thereby transforming the delivery of women's health services.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Women's Health Therapeutics Market by Therapeutic Area

• Market Overview
• Hormone Therapies
• Contraceptives
• Reproductive Health Drugs
• and others

Global Women's Health Therapeutics Market by Indication

• Market Overview
• Menopause
• Contraception
• Hormone-related Cancers
• Reproductive Disorders
• and others

Global Women's Health Therapeutics Market by Distribution channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• and Others

Global Women's Health Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments